Condition: HIV Infection · Cardiovascular Diseases (CVD) · Sponsor: Instituto de Investigación Hospital Universitario La Paz
The purpose of this study is to evaluate whether colchicine can reduce coronary artery inflammation in people living with HIV and high cardiovascular risk. Participants will be randomized 1:1 to receive either colchicine or placebo for 96 weeks in a double-blind, multicenter clinical trial. Neither participants nor researchers will know which treatment is assigned during the study. The primary endpoint is the change in coronary artery inflammation measured by coronary computed tomography angiography (CCTA) after 96 weeks.
This description comes directly from the study's public registry record.
José Ignacio Bernardino de la Serna, MD, PhD · (+34) 915683515 · Jose.bernardino@salud.madrid.org
Always discuss trial participation with your own doctor first.
| Hospital Universitario Vall d' Hebron | Barcelona, Spain | Recruiting |
| Hospital La Paz | Madrid, Spain | Recruiting |
| Fundación Jiménez Díaz | Madrid, Spain | Not Yet Recruiting |
| Hospital Universitario de la Princesa | Madrid, Spain | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07704164